SVP, Chief Accounting Officer · Akebia Therapeutics, Inc. · Common Stock
Side
A
Value
—
Shares
79.0K
Price
—
Executed
Jan 30, 2026
Disclosed
Feb 3, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 30 executedFeb 3, 2026 disclosed
AKBA · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+9 / 25
No reported dollar value · 29.3% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Malabre Richard C filed this Form 4 reporting a grant or award of AKBA on Jan 30, 2026. It became public on Feb 3, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
SVP, Chief Accounting Officer
Malabre Richard Ccik:0002007730
Issuer
Akebia Therapeutics, Inc.cik:0001517022
Revision history · 0
No field has changed since this record was first ingested.
